Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer
    Hatem, Elie
    Azzi, Sandy
    El Banna, Nadine
    He, Tiantian
    Heneman-Masurel, Amelie
    Vernis, Laurence
    Baille, Dorothee
    Masson, Vanessa
    Dingli, Florent
    Loew, Damarys
    Azzarone, Bruno
    Eid, Pierre
    Baldacci, Giuseppe
    Huang, Meng-Er
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (06): : 597 - 608
  • [42] Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
    Meric-Bernstam, Funda
    Yuca, Erkan
    Evans, Kurt W.
    Zhao, Ming
    Maejima, Takanori
    Karibe, Tsuyoshi
    Raso, Maria Gabriela
    Tang, Ximing
    Zheng, Xiaofeng
    Rizvi, Yasmeen Qamar
    Akcakanat, Argun
    Scott, Stephen M.
    Wang, Bailiang
    Byers, Lauren A.
    Tripathy, Debu
    Okajima, Daisuke
    Damodaran, Senthil
    CLINICAL CANCER RESEARCH, 2025, 31 (03) : 573 - 587
  • [43] Bioinformatic analysis of drug targets for triple-negative breast cancer
    Li, Xiao-Wei
    Kang, Chun-Bo
    Chi, Xiao-Qian
    Liu, Tie-Jun
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 882 - 883
  • [44] Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
    Bardia, Aditya
    Krop, Ian
    Meric-Bernstam, Funda
    Tolcher, Anthony W.
    Mukohara, Toru
    Lisberg, Aaron
    Shimizu, Toshio
    Hamilton, Erika
    Spira, Alexander I.
    Papadopoulos, Kyriakos P.
    Greenberg, Jonathan
    Gu, Wen
    Kobayashi, Fumiaki
    Zebger-Gong, Hong
    Kawasaki, Yui
    Wong, Rie
    Kogawa, Takahiro
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer
    Zhou, Dan-Dan
    Bai, Wei-Qi
    Zhai, Xiao-Tian
    Sun, Li-Ping
    Zhen, Yong-Su
    Li, Zhuo-Rong
    Miao, Qing-Fang
    MILITARY MEDICAL RESEARCH, 2021, 8 (01)
  • [46] Triple-Negative Breast Cancer: Not Entirely Negative
    Leone, Jose Pablo
    Puhalla, Shannon
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 856 - +
  • [47] Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer
    Yao, Hang-Ping
    Suthe, Sreedhar Reddy
    Hudson, Rachel
    Wang, Ming-Hai
    DRUG DISCOVERY TODAY, 2020, 25 (07) : 1160 - 1173
  • [48] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187
  • [49] Novel immune targets for the treatment of triple-negative breast cancer
    Corti, Chiara
    Nicolo, Eleonora
    Curigliano, Giuseppe
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (10) : 815 - 834
  • [50] Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
    Das, Amiya
    Agarwal, Pallavi
    Jain, Gaurav Kumar
    Aggarwal, Geeta
    Lather, Viney
    Pandita, Deepti
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (03) : 515 - 550
12345